BORTOLOT, MARTINA
BORTOLOT, MARTINA
DMED - DIPARTIMENTO DI MEDICINA
Advancing leptomeningeal metastases treatment in EGFR-mutated non-small cell lung cancer: lessons from the BLOSSOM trial
2025-01-01 Bortolot, M.; Huijs, J. W. J.; Brandsma, D.; Compter, A.; van Geel, R. M. J. M.; Hendriks, L. E. L.
Assessing the impact of structured reporting on learning how to report lung cancer staging CT: A triple cohort study on inexperienced readers
2024-01-01 Cereser, L; Cortiula, F; Simiele, C; Peruzzi, V; Bortolot, M; Tullio, A; Como, G; Zuiani, C; Girometti, R
Comparative efficacy of immunotherapy-based treatment versus chemotherapy-only in patients with unresectable NSCLC with disease progression post chemoradiation and durvalumab
2025-01-01 Cortiula, F.; Kutiel, T. S.; Hsu, M. L.; Hendriks, L. E. L.; Nassar, A. H.; Moskovitz, M.; Kim, S. Y.; Mirsky, M. M.; Jayakrishnan, R.; Bortolot, M.; Saddi, J.; Borghetti, P.; Chung, M. J.; Filippi, A. R.; De Ruysscher, D.; Bar, J.
De-Escalation Strategies With Immune Checkpoint Blockers in Non-Small Cell Lung Cancer: Do We Already Have Enough Evidence?
2025-01-01 Remon, J.; Bortolot, M.; Bironzo, P.; Cortiula, F.; Menis, J.; Brandao, M.; Naidoo, J.; Van Geel, R.; Reguart, N.; Arrieta, O.; Mountzios, G.; Hendriks, L. E. L.; Besse, B.
Immunotherapy in NSCLC Patients with Brain Metastases
2022-01-01 Buriolla, Silvia; Pelizzari, Giacomo; Corvaja, Carla; Alberto, Martina; Targa, Giada; Bortolot, Martina; Torresan, Sara; Cortiula, Francesco; Fasola, Gianpiero; Follador, Alessandro
Immunotherapy in Oncogene-Addicted NSCLC: Evidence and Therapeutic Approaches
2025-01-01 Foffano, L.; Bertoli, E.; Bortolot, M.; Torresan, S.; De Carlo, E.; Stanzione, B.; Del Conte, A.; Puglisi, F.; Spina, M.; Bearz, A.
Impact of Immune Checkpoint Inhibitors and Local Radical Treatment on Survival Outcomes in Synchronous Oligometastatic NSCLC
2025-01-01 Jongbloed, M.; Bartolomeo, V.; Bortolot, M.; Darwesh, S.; Huijs, J. W. J.; Dursun, S.; Degens, J.; van den Borne, B. E. E. M.; Youssef-El Soud, M.; Westenend, M.; Pitz, C.; De Ruysscher, D. K. M.; Hendriks, L. E. L.
Liquid biopsy in colorectal cancer: Onward and upward
2024-01-01 Torresan, S.; de Scordilli, M.; Bortolot, M.; Di Nardo, P.; Foltran, L.; Fumagalli, A.; Guardascione, M.; Ongaro, E.; Puglisi, F.
Matters of the Heart: Cardiotoxicity Related to Target Therapy in Oncogene-Addicted Non-Small Cell Lung Cancer
2025-01-01 Torresan, S.; Bortolot, M.; De Carlo, E.; Bertoli, E.; Stanzione, B.; Del Conte, A.; Spina, M.; Bearz, A.
Navigating Therapeutic Challenges in BRAF-Mutated NSCLC: Non-V600 Mutations, Immunotherapy, and Overcoming Resistance
2024-01-01 Bortolot, M.; Torresan, S.; De Carlo, E.; Bertoli, E.; Stanzione, B.; Del Conte, A.; Spina, M.; Bearz, A.
Prognostic and Predictive Biomarkers of Oligometastatic NSCLC: New Insights and Clinical Applications
2024-01-01 Jongbloed, M.; Bortolot, M.; Wee, L.; Huijs, J. W. J.; Bellezo, M.; Vaes, R. D. W.; Aboubakar Nana, F.; Hartemink, K. J.; De Ruysscher, D. K. M.; Hendriks, L. E. L.
Targeted Therapy in Mesotheliomas: Uphill All the Way
2024-01-01 Bertoli, E.; De Carlo, E.; Bortolot, M.; Stanzione, B.; Del Conte, A.; Spina, M.; Bearz, A.
Treatment of unresectable stage III non-small cell lung cancer for patients who are under-represented in clinical trials
2024-01-01 Bortolot, M.; Cortiula, F.; Fasola, G.; De Ruysscher, D.; Naidoo, J.; Hendriks, L. E. L.
| Titolo | Data di pubblicazione | Autore(i) | File |
|---|---|---|---|
| Advancing leptomeningeal metastases treatment in EGFR-mutated non-small cell lung cancer: lessons from the BLOSSOM trial | 1-gen-2025 | Bortolot, M.; Huijs, J. W. J.; Brandsma, D.; Compter, A.; van Geel, R. M. J. M.; Hendriks, L. E. L. | |
| Assessing the impact of structured reporting on learning how to report lung cancer staging CT: A triple cohort study on inexperienced readers | 1-gen-2024 | Cereser, L; Cortiula, F; Simiele, C; Peruzzi, V; Bortolot, M; Tullio, A; Como, G; Zuiani, C; Girometti, R | |
| Comparative efficacy of immunotherapy-based treatment versus chemotherapy-only in patients with unresectable NSCLC with disease progression post chemoradiation and durvalumab | 1-gen-2025 | Cortiula, F.; Kutiel, T. S.; Hsu, M. L.; Hendriks, L. E. L.; Nassar, A. H.; Moskovitz, M.; Kim, S. Y.; Mirsky, M. M.; Jayakrishnan, R.; Bortolot, M.; Saddi, J.; Borghetti, P.; Chung, M. J.; Filippi, A. R.; De Ruysscher, D.; Bar, J. | |
| De-Escalation Strategies With Immune Checkpoint Blockers in Non-Small Cell Lung Cancer: Do We Already Have Enough Evidence? | 1-gen-2025 | Remon, J.; Bortolot, M.; Bironzo, P.; Cortiula, F.; Menis, J.; Brandao, M.; Naidoo, J.; Van Geel, R.; Reguart, N.; Arrieta, O.; Mountzios, G.; Hendriks, L. E. L.; Besse, B. | |
| Immunotherapy in NSCLC Patients with Brain Metastases | 1-gen-2022 | Buriolla, Silvia; Pelizzari, Giacomo; Corvaja, Carla; Alberto, Martina; Targa, Giada; Bortolot, Martina; Torresan, Sara; Cortiula, Francesco; Fasola, Gianpiero; Follador, Alessandro | |
| Immunotherapy in Oncogene-Addicted NSCLC: Evidence and Therapeutic Approaches | 1-gen-2025 | Foffano, L.; Bertoli, E.; Bortolot, M.; Torresan, S.; De Carlo, E.; Stanzione, B.; Del Conte, A.; Puglisi, F.; Spina, M.; Bearz, A. | |
| Impact of Immune Checkpoint Inhibitors and Local Radical Treatment on Survival Outcomes in Synchronous Oligometastatic NSCLC | 1-gen-2025 | Jongbloed, M.; Bartolomeo, V.; Bortolot, M.; Darwesh, S.; Huijs, J. W. J.; Dursun, S.; Degens, J.; van den Borne, B. E. E. M.; Youssef-El Soud, M.; Westenend, M.; Pitz, C.; De Ruysscher, D. K. M.; Hendriks, L. E. L. | |
| Liquid biopsy in colorectal cancer: Onward and upward | 1-gen-2024 | Torresan, S.; de Scordilli, M.; Bortolot, M.; Di Nardo, P.; Foltran, L.; Fumagalli, A.; Guardascione, M.; Ongaro, E.; Puglisi, F. | |
| Matters of the Heart: Cardiotoxicity Related to Target Therapy in Oncogene-Addicted Non-Small Cell Lung Cancer | 1-gen-2025 | Torresan, S.; Bortolot, M.; De Carlo, E.; Bertoli, E.; Stanzione, B.; Del Conte, A.; Spina, M.; Bearz, A. | |
| Navigating Therapeutic Challenges in BRAF-Mutated NSCLC: Non-V600 Mutations, Immunotherapy, and Overcoming Resistance | 1-gen-2024 | Bortolot, M.; Torresan, S.; De Carlo, E.; Bertoli, E.; Stanzione, B.; Del Conte, A.; Spina, M.; Bearz, A. | |
| Prognostic and Predictive Biomarkers of Oligometastatic NSCLC: New Insights and Clinical Applications | 1-gen-2024 | Jongbloed, M.; Bortolot, M.; Wee, L.; Huijs, J. W. J.; Bellezo, M.; Vaes, R. D. W.; Aboubakar Nana, F.; Hartemink, K. J.; De Ruysscher, D. K. M.; Hendriks, L. E. L. | |
| Targeted Therapy in Mesotheliomas: Uphill All the Way | 1-gen-2024 | Bertoli, E.; De Carlo, E.; Bortolot, M.; Stanzione, B.; Del Conte, A.; Spina, M.; Bearz, A. | |
| Treatment of unresectable stage III non-small cell lung cancer for patients who are under-represented in clinical trials | 1-gen-2024 | Bortolot, M.; Cortiula, F.; Fasola, G.; De Ruysscher, D.; Naidoo, J.; Hendriks, L. E. L. |